Lymphoid Malignancies
20
2
2
9
Key Insights
Highlights
Success Rate
56% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
35.0%
7 terminated out of 20 trials
56.3%
-30.3% vs benchmark
5%
1 trials in Phase 3/4
78%
7 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 9 completed trials
Clinical Trials (20)
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
Allogeneic iNKT Cell Therapy (agenT-797) After SCT
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies
RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies
Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies
ACY-1215 for Relapsed/Refractory Lymphoid Malignancies
Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT
A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies
Intra-Osseous Co-Transplant of UCB and hMSC
Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820
Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation
Fludarabine/Busulfan and Cyclophosphamide Conditioning for Adult Lymphoid Malignancies
Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System
A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies
A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies
RTA 402 in Advanced Solid Tumors or Lymphoid Malignancies
Safety and Tolerability of CHR-2845 to Treat Haematological Diseases or Lymphoid Malignancies
Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders